Alyeska Investment Group’s Avidity Biosciences RNAM Stock Holding History

Alyeska Investment Group’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-175,000	Closed	-$7.62M	–	711
2025 Q3	$7.62M	Buy	175,000 +50,000	+40%	+$2.02M	0.02%	415
2025 Q2	$3.55M	Buy	125,000 +25,000	+25%	+$745K	0.01%	448
2025 Q1	$2.95M	Buy	100,000 +50,000	+100%	+$1.56M	0.01%	398
2024 Q4	$1.45M	Sell	50,000 -25,000	-33%	-$1.04M	0.01%	478
2024 Q3	$3.44M	Sell	75,000 -75,000	-50%	-$3.25M	0.02%	383
2024 Q2	$6.13M	Buy	+150,000	New	+$4.3M	0.04%	314
2020 Q4	–	Sell	-113,527	Closed	-$3.2M	–	588
2020 Q3	$3.2M	Sell	113,527 -133,300	-54%	-$3.85M	0.05%	302
2020 Q2	$6.97M	Buy	+246,827	New	+$7.12M	0.11%	231

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's RNAM Position: Q4 2025 in Review

Alyeska Investment Group sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 175,000 shares — an estimated $7.62M sold.

Alyeska Investment Group first reported a position in RNAM in Q2 2020 and held it in 8 quarters. The position peaked at $7.62M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Alyeska Investment Group reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Alyeska Investment Group sold 175,000 Avidity Biosciences shares in Q4 2025, an estimated $7.62M.
Alyeska Investment Group first reported a position in Avidity Biosciences in Q2 2020 and held it in 8 quarters.
Alyeska Investment Group's Avidity Biosciences position peaked at $7.62M in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.